Comparison of the Alpha and Beta Blocking Drug, Labetalol, and Methyl Dopa in the Treatment of Moderate and Severe Pregnancy-Induced Hypertension

Lamming, G. D.; Pipkin, Fiona Broughton; Symonds, E. M.

doi:10.3109/10641968009037147

Cited by 70 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further evidence to support the suggestion of Prichard et al (1975), that labetalol was a drug that could control the blood pressure in patients previously needing large doses of methyldopa, was provided by the work of Dargie et al, (1976 (Lamming et al, 1980).…”

Section: Labetalol and 0-blockers Plus Hydrallazinementioning

confidence: 84%

Comparison of labetalol with other anti‐hypertensive drugs.

Prichard¹,

Richards²

1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The anti‐hypertensive effects of labetalol have been compared and contrasted with other groups of anti‐hypertensive drugs in this review of the published literature. 2 The data show that the pharmacological and haemodynamic profile of labetalol in man is distinctly different from that of other specific anti‐hypertensive agents; namely the properties of competitive alpha‐and beta‐adrenoceptor blockade leading to haemodynamic effects of reduced blood pressure and peripheral vascular resistance with little accompanying changes in resting heart rate or cardiac output. 3 The anti‐hypertensive effects of labetalol are dose related. In fixed dose comparative studies equivalent anti‐ hypertensive effects to those of labetalol have been shown for individual drugs of the beta‐adrenoceptor‐blocking and diuretic groups. In dose titration studies, equivalent anti‐hypertensive effects at given doses of labetalol have been demonstrated for drugs of the following types: beta‐adrenoceptor blockers, beta‐blockers plus diuretics, methyldopa, adrenergic neurone blockers and the combination of beta‐blockers plus a peripheral vasodilator. 4 Comparing side‐effect liabilities, it is clear that quantitatively labetalol produces no greater burden of side‐effects than drugs of the beta‐adrenoceptor‐ blocking group. Qualitative differences, however, do exist; in particular, symptomatic postural hypotension is dose related and is more likely to occur when excessive doses (greater than 2 g daily) are used.

show abstract

Section: Labetalol and 0-blockers Plus Hydrallazinementioning

confidence: 84%

Comparison of labetalol with other anti‐hypertensive drugs.

Prichard¹,

Richards²

1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…This is due in great part to the fact that the studies were carried out on maternal populations whose clinical and pathological states were different to a very important degree, and also other varying factors, not precised in the published papers, but also likely to play an important role in the immediate respiratory adaptation of the newborn. Thus, for the same drug, labetalol, in comparable groups of children, Lamming et al [1980] found no respiratory problems, whilst 36.8% of the newborn in the study by Redman [1982] had to be intubated.…”

Section: Respiratory Effectsmentioning

confidence: 99%

Fetal and Neonatal Effects of the Beta-Adrenoceptor Blocking Agents

Mj¹

1987

Dev Pharmacol Ther

View full text Add to dashboard Cite

The placental transfer of beta-adrenoceptor blocking agents has been well established in the last years. Randomized and/or controlled studies have given a less pessimistic view of the consequences of these drugs on the fetal and neonatal adaptation. In fact, the beta-blockers are able to produce hypotension, bradycardia, respiratory troubles in the newborn infant, troubles which are generally slight when the neonates are full-term. However, even if in good clinical conditions, this kind of neonate should be carefully monitored for at least the first 2 days of life.

show abstract

“…Three antihypertensive drugsnifedipine, methyldopa and labetalol have been demonstrated to be safe for use in the pregnant women and are commonly used for the management of various hypertensive disorders during pregnancy. [10][11][12][13][14][15] Nifedipine is a calcium channel blocker. Methyldopa is a centrallyacting adrenergic antagonist that acts by stimulation of the central alpha 2 receptors, leading to a decrease in sympathetic nerve activity with resultant arterial dilatation ABSTRACT Background: Pregnancy-induced hypertension is associated with various adverse fetal and maternal outcomes.…”

Section: Introductionmentioning

confidence: 99%

Comparative evaluation of antihypertensive drugs in the management of pregnancy-induced hypertension

Patel

Gadhavi

Gorasia

et al. 2012

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Pregnancy-induced hypertension is associated with various adverse fetal and maternal outcomes. The use of anti-hypertensive drugs in pregnancy is controversial. We conducted a prospective study to evaluate the comparative effectiveness and safety of nifedipine, methyldopa and labetalol monotherapy in patients with pregnancy-induced hypertension. Methods: A total of 60 pregnant women with blood pressure of 140/90 mm Hg or more with ≥1+ proteinuria between 20 and 38 weeks of gestation were randomly allocated to receive nifedipine (n=20), methyldopa (n=20) or labetalol (n=20). Blood pressure was measured at 0, 6, 24, 48 and 72 h of initiation of antihypertensive drugs. Patients were also followed up for development of adverse drug effects during this period. Results: Antihypertensive treatment with methyldopa was associated with reduction in systolic blood pressure (SBP) by 50 mmHg and diastolic blood pressure (DBP) by 30 mmHg at 72 h. For the same period treatment with nifedipine was associated with reduction in SBP by 54 mmHg and DBP by 30 mmHg. Treatment with labetalol was associated with reduction in SBP by 70 mmHg and DBP by 36 mmHg at 72 h. Conclusions: Labetalol was more effective than methyldopa and nifedipine in controlling blood pressure in patients with pregnancy-induced hypertension while methyldopa and nifedipine are equally effective in controlling blood pressure. [Int J Basic Clin Pharmacol 2012; 1(3.000): 174-177

show abstract

Comparison of the Alpha and Beta Blocking Drug, Labetalol, and Methyl Dopa in the Treatment of Moderate and Severe Pregnancy-Induced Hypertension

Cited by 70 publications

References 18 publications

Comparison of labetalol with other anti‐hypertensive drugs.

Comparison of labetalol with other anti‐hypertensive drugs.

Fetal and Neonatal Effects of the Beta-Adrenoceptor Blocking Agents

Comparative evaluation of antihypertensive drugs in the management of pregnancy-induced hypertension

Contact Info

Product

Resources

About